Document › Details

Epigenomics AG. (1/11/10). "Press Release: Epigenomics AG. Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S. (Ad Hoc Announcement pursuant to §15 WpHG)".

Region Region United States (USA)
Organisations Organisation Quest Diagnostics Inc. (NYSE: DGX)
  Group Quest Diagnostics (Group)
  Organisation 2 Epigenomics AG
  Group Epigenomics (Group)
Products Product colorectal cancer test
  Product 2 Septin 9 biomarker
Index terms Index term Quest Diagnostics–Epigenomics: Septin 9 biomarker, 200801– license ww non-excl commercial for detection of colorectal cancer
  Index term 2 launch (product/service)
     
Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs that Quest Diagnostics Incorporated, Madison, NJ, U.S.A., today introduced its laboratory developed blood test for aiding the detection of colorectal cancer in the United States. The test was independently developed by Quest Diagnostics based on Epigenomics' proprietary DNA methylation biomarker Septin9 and certain proprietary technologies that were licensed to Quest Diagnostics in 2008. The introduction follows the successful completion of the clinical validation of this laboratory developed test in November 2009 and the release of the test for offering to doctors and patients in December 2009.

Physicians in the United States may order the test through a Quest Diagnostics regional laboratory. With the introduction of this test, Epigenomics continues executing its dual business model of non-exclusive licensing and direct commercialization of its cancer molecular diagnostic biomarkers and products.

End of Ad hoc

Further Information

For further information please see today's press release by Quest Diagnostics at http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-news

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

   
Record changed: 2010-07-21

More documents for Quest Diagnostics (Group)

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
» top